Key result
Finerenone is linked to ~67% lower ischemic stroke risk vs non-users in T2D and CKD.
Why the study?
Finerenone improves composite renal and cardiovascular outcomes in trials, but ischemic stroke has mostly been evaluated within composite endpoints and real-world evidence focusing on it remains limited.
Does finerenone reduce incident ischemic stroke in adults with T2DM and CKD?
Population
125,086 adults with newly diagnosed T2DM who developed CKD
Comparison
Finerenone users vs non-users
Design
Retrospective propensity score-matched cohort study
Authors
Loading...
Should not yet change practice for stroke prevention in T2DM-CKD; leaves open causal benefit pending randomized confirmation.
Cohort (n=125,086)
Yes
Does finerenone reduce incident ischemic stroke in adults with T2DM and CKD?
Hazard Ratio: 0.33 (95% CI 0.26–0.42)
In a real-world cohort of patients with T2DM and CKD, finerenone use was associated with a significantly lower risk of incident ischemic stroke.
Chuang et al. (2026) conducted a cohort in Type 2 diabetes and chronic kidney disease (n=125,086). Finerenone vs. non-users was evaluated on incident ischemic stroke (adjusted HR 0.33, 95% CI 0.26-0.42). Finerenone use was associated with a lower hazard of ischemic stroke compared to non-users in adults with type 2 diabetes and chronic kidney disease (adjusted HR 0.33; 95% CI 0.26-0.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: